Andrew Clear
YOU?
Author Swipe
View article: Autophagy is an upstream mediator of chromatin dynamics in normal and autoimmune germinal center B cells
Autophagy is an upstream mediator of chromatin dynamics in normal and autoimmune germinal center B cells Open
Germinal center (GC) B cells are pivotal in establishing a robust humoral immune response and long-term serological immunity while maintaining antibody self-tolerance. GC B cells rely on autophagy for antigen presentation and homeostatic m…
View article: Delays to Diagnosis of Peripheral T-Cell Lymphoma and Clinical Utility of Molecular Profiling: A UK Multicentre Real-World Study
Delays to Diagnosis of Peripheral T-Cell Lymphoma and Clinical Utility of Molecular Profiling: A UK Multicentre Real-World Study Open
Background: Peripheral T-cell lymphomas (PTCL) comprise a group of heterogeneous and aggressive lymphomas, often associated with poor outcomes. Histological heterogeneity and variability in clinical presentation and tissue biopsies are pos…
View article: Multi-Modal Analysis Reveals the Differences between Double Expressor and Non-Double Expressor Primary Central Nervous System Lymphomas
Multi-Modal Analysis Reveals the Differences between Double Expressor and Non-Double Expressor Primary Central Nervous System Lymphomas Open
Introduction Primary central nervous system lymphoma (PCNSL) is a rare B-cell lymphoma with an aggressive course. We recently identified, double expression of BCL2 and MYC (DE) as a biomarker of aggressive disease in PCNSL (Poynton et al, …
View article: <i>CREBBP</i> histone acetyltransferase domain mutations predict response to mTOR inhibition in relapsed/refractory follicular lymphoma
<i>CREBBP</i> histone acetyltransferase domain mutations predict response to mTOR inhibition in relapsed/refractory follicular lymphoma Open
Summary Despite the clinical and molecular heterogeneity of follicular lymphoma (FL), there remains a lack of biomarker‐directed therapeutic approaches in routine clinical practice, with the notable exception of the EZH2 inhibitor tazemeto…
View article: Genetic and Microenvironment Features Do Not Distinguish Follicular Lymphoma Patients Requiring Immediate or Deferred Treatment
Genetic and Microenvironment Features Do Not Distinguish Follicular Lymphoma Patients Requiring Immediate or Deferred Treatment Open
International audience
View article: Supplementary Figure S1 from Poor Concordance among Nine Immunohistochemistry Classifiers of Cell-of-Origin for Diffuse Large B-Cell Lymphoma: Implications for Therapeutic Strategies
Supplementary Figure S1 from Poor Concordance among Nine Immunohistochemistry Classifiers of Cell-of-Origin for Diffuse Large B-Cell Lymphoma: Implications for Therapeutic Strategies Open
PDF file 265K, Supplementary Figure 1: Immunohistochemistry results for each antibody (A) BCL2; (B) CD10; (C) MUM1; (D) LMO2; (E) GCET1; (F) BCL6; (G) FOXP1. Original magnification: x20
View article: Supplementary Table S2 from Poor Concordance among Nine Immunohistochemistry Classifiers of Cell-of-Origin for Diffuse Large B-Cell Lymphoma: Implications for Therapeutic Strategies
Supplementary Table S2 from Poor Concordance among Nine Immunohistochemistry Classifiers of Cell-of-Origin for Diffuse Large B-Cell Lymphoma: Implications for Therapeutic Strategies Open
PDF file 51K, Supplementary Table S2 Distribution of R-CHOP treated patients diagnosed in the two institutions according to the nine IHC classifiers
View article: Supplementary Table S1 from Poor Concordance among Nine Immunohistochemistry Classifiers of Cell-of-Origin for Diffuse Large B-Cell Lymphoma: Implications for Therapeutic Strategies
Supplementary Table S1 from Poor Concordance among Nine Immunohistochemistry Classifiers of Cell-of-Origin for Diffuse Large B-Cell Lymphoma: Implications for Therapeutic Strategies Open
PDF file 54K, Supplementary Table S1 Primary antibodies and conditions of use
View article: Supplementary table 3 from Neoadjuvant Chemotherapy Modulates the Immune Microenvironment in Metastases of Tubo-Ovarian High-Grade Serous Carcinoma
Supplementary table 3 from Neoadjuvant Chemotherapy Modulates the Immune Microenvironment in Metastases of Tubo-Ovarian High-Grade Serous Carcinoma Open
Cohort per experiment
View article: Supplementary Materials and Methods, Supplementary Figures 1-4, Supplementary Table Legends, Supplementary Figure Legends from Neoadjuvant Chemotherapy Modulates the Immune Microenvironment in Metastases of Tubo-Ovarian High-Grade Serous Carcinoma
Supplementary Materials and Methods, Supplementary Figures 1-4, Supplementary Table Legends, Supplementary Figure Legends from Neoadjuvant Chemotherapy Modulates the Immune Microenvironment in Metastases of Tubo-Ovarian High-Grade Serous Carcinoma Open
Supplementary Table 1. Baseline characteristics and histopathological data of the patients receiving neoadjuvant chemotherapy (NACT) and analysed in this study; Supplementary Table 2. Baseline characteristics of the cohort of patients unde…
View article: Data from Poor Concordance among Nine Immunohistochemistry Classifiers of Cell-of-Origin for Diffuse Large B-Cell Lymphoma: Implications for Therapeutic Strategies
Data from Poor Concordance among Nine Immunohistochemistry Classifiers of Cell-of-Origin for Diffuse Large B-Cell Lymphoma: Implications for Therapeutic Strategies Open
Purpose: The opportunity to improve therapeutic choices on the basis of molecular features of the tumor cells is on the horizon in diffuse large B-cell lymphoma (DLBCL). Agents such as bortezomib exhibit selective activity against the poor…
View article: Supplementary table 1 from Neoadjuvant Chemotherapy Modulates the Immune Microenvironment in Metastases of Tubo-Ovarian High-Grade Serous Carcinoma
Supplementary table 1 from Neoadjuvant Chemotherapy Modulates the Immune Microenvironment in Metastases of Tubo-Ovarian High-Grade Serous Carcinoma Open
Total patient cohort
View article: Data from Neoadjuvant Chemotherapy Modulates the Immune Microenvironment in Metastases of Tubo-Ovarian High-Grade Serous Carcinoma
Data from Neoadjuvant Chemotherapy Modulates the Immune Microenvironment in Metastases of Tubo-Ovarian High-Grade Serous Carcinoma Open
Purpose: The purpose of this study was to assess the effect of neoadjuvant chemotherapy (NACT) on immune activation in stage IIIC/IV tubo-ovarian high-grade serous carcinoma (HGSC), and its relationship to treatment response.Experimental D…
View article: Data from Neoadjuvant Chemotherapy Modulates the Immune Microenvironment in Metastases of Tubo-Ovarian High-Grade Serous Carcinoma
Data from Neoadjuvant Chemotherapy Modulates the Immune Microenvironment in Metastases of Tubo-Ovarian High-Grade Serous Carcinoma Open
Purpose: The purpose of this study was to assess the effect of neoadjuvant chemotherapy (NACT) on immune activation in stage IIIC/IV tubo-ovarian high-grade serous carcinoma (HGSC), and its relationship to treatment response.Experimental D…
View article: Supplementary table 1 from Neoadjuvant Chemotherapy Modulates the Immune Microenvironment in Metastases of Tubo-Ovarian High-Grade Serous Carcinoma
Supplementary table 1 from Neoadjuvant Chemotherapy Modulates the Immune Microenvironment in Metastases of Tubo-Ovarian High-Grade Serous Carcinoma Open
Total patient cohort
View article: Supplementary table 2 from Neoadjuvant Chemotherapy Modulates the Immune Microenvironment in Metastases of Tubo-Ovarian High-Grade Serous Carcinoma
Supplementary table 2 from Neoadjuvant Chemotherapy Modulates the Immune Microenvironment in Metastases of Tubo-Ovarian High-Grade Serous Carcinoma Open
PDS cohort
View article: Data from Poor Concordance among Nine Immunohistochemistry Classifiers of Cell-of-Origin for Diffuse Large B-Cell Lymphoma: Implications for Therapeutic Strategies
Data from Poor Concordance among Nine Immunohistochemistry Classifiers of Cell-of-Origin for Diffuse Large B-Cell Lymphoma: Implications for Therapeutic Strategies Open
Purpose: The opportunity to improve therapeutic choices on the basis of molecular features of the tumor cells is on the horizon in diffuse large B-cell lymphoma (DLBCL). Agents such as bortezomib exhibit selective activity against the poor…
View article: Supplementary Figure Legend from Poor Concordance among Nine Immunohistochemistry Classifiers of Cell-of-Origin for Diffuse Large B-Cell Lymphoma: Implications for Therapeutic Strategies
Supplementary Figure Legend from Poor Concordance among Nine Immunohistochemistry Classifiers of Cell-of-Origin for Diffuse Large B-Cell Lymphoma: Implications for Therapeutic Strategies Open
PDF file 44K, Legend for Supplementary Figure 1
View article: Supplementary Figure S1 from Poor Concordance among Nine Immunohistochemistry Classifiers of Cell-of-Origin for Diffuse Large B-Cell Lymphoma: Implications for Therapeutic Strategies
Supplementary Figure S1 from Poor Concordance among Nine Immunohistochemistry Classifiers of Cell-of-Origin for Diffuse Large B-Cell Lymphoma: Implications for Therapeutic Strategies Open
PDF file 265K, Supplementary Figure 1: Immunohistochemistry results for each antibody (A) BCL2; (B) CD10; (C) MUM1; (D) LMO2; (E) GCET1; (F) BCL6; (G) FOXP1. Original magnification: x20
View article: Supplementary Table S1 from Poor Concordance among Nine Immunohistochemistry Classifiers of Cell-of-Origin for Diffuse Large B-Cell Lymphoma: Implications for Therapeutic Strategies
Supplementary Table S1 from Poor Concordance among Nine Immunohistochemistry Classifiers of Cell-of-Origin for Diffuse Large B-Cell Lymphoma: Implications for Therapeutic Strategies Open
PDF file 54K, Supplementary Table S1 Primary antibodies and conditions of use
View article: Supplementary Table S2 from Poor Concordance among Nine Immunohistochemistry Classifiers of Cell-of-Origin for Diffuse Large B-Cell Lymphoma: Implications for Therapeutic Strategies
Supplementary Table S2 from Poor Concordance among Nine Immunohistochemistry Classifiers of Cell-of-Origin for Diffuse Large B-Cell Lymphoma: Implications for Therapeutic Strategies Open
PDF file 51K, Supplementary Table S2 Distribution of R-CHOP treated patients diagnosed in the two institutions according to the nine IHC classifiers
View article: Supplementary table 2 from Neoadjuvant Chemotherapy Modulates the Immune Microenvironment in Metastases of Tubo-Ovarian High-Grade Serous Carcinoma
Supplementary table 2 from Neoadjuvant Chemotherapy Modulates the Immune Microenvironment in Metastases of Tubo-Ovarian High-Grade Serous Carcinoma Open
PDS cohort
View article: Supplementary Figure Legend from Poor Concordance among Nine Immunohistochemistry Classifiers of Cell-of-Origin for Diffuse Large B-Cell Lymphoma: Implications for Therapeutic Strategies
Supplementary Figure Legend from Poor Concordance among Nine Immunohistochemistry Classifiers of Cell-of-Origin for Diffuse Large B-Cell Lymphoma: Implications for Therapeutic Strategies Open
PDF file 44K, Legend for Supplementary Figure 1
View article: Supplementary table 3 from Neoadjuvant Chemotherapy Modulates the Immune Microenvironment in Metastases of Tubo-Ovarian High-Grade Serous Carcinoma
Supplementary table 3 from Neoadjuvant Chemotherapy Modulates the Immune Microenvironment in Metastases of Tubo-Ovarian High-Grade Serous Carcinoma Open
Cohort per experiment
View article: Supplementary Materials and Methods, Supplementary Figures 1-4, Supplementary Table Legends, Supplementary Figure Legends from Neoadjuvant Chemotherapy Modulates the Immune Microenvironment in Metastases of Tubo-Ovarian High-Grade Serous Carcinoma
Supplementary Materials and Methods, Supplementary Figures 1-4, Supplementary Table Legends, Supplementary Figure Legends from Neoadjuvant Chemotherapy Modulates the Immune Microenvironment in Metastases of Tubo-Ovarian High-Grade Serous Carcinoma Open
Supplementary Table 1. Baseline characteristics and histopathological data of the patients receiving neoadjuvant chemotherapy (NACT) and analysed in this study; Supplementary Table 2. Baseline characteristics of the cohort of patients unde…
View article: Lack of reproducibility of histopathological features in <i>MYC</i>‐rearranged large B cell lymphoma using digital whole slide images: a study from the Lunenburg lymphoma biomarker consortium
Lack of reproducibility of histopathological features in <i>MYC</i>‐rearranged large B cell lymphoma using digital whole slide images: a study from the Lunenburg lymphoma biomarker consortium Open
Aims Subclassification of large B cell lymphoma (LBCL) is challenging due to the overlap in histopathological, immunophenotypical and genetic data. In particular, the criteria to separate diffuse large B cell lymphoma (DLBCL) and high‐grad…
View article: Genomic and microenvironmental landscape of stage I follicular lymphoma, compared with stage III/IV
Genomic and microenvironmental landscape of stage I follicular lymphoma, compared with stage III/IV Open
Although the genomic and immune microenvironmental landscape of follicular lymphoma (FL) has been extensively investigated, little is known about the potential biological differences between stage I and stage III/IV disease. Using next-gen…
View article: Longitudinal expression profiling identifies a poor risk subset of patients with ABC-type diffuse large B-cell lymphoma
Longitudinal expression profiling identifies a poor risk subset of patients with ABC-type diffuse large B-cell lymphoma Open
Despite the effectiveness of immuno-chemotherapy, 40% of patients with diffuse large B-cell lymphoma (DLBCL) experience relapse or refractory disease. Longitudinal studies have previously focused on the mutational landscape of relapse but …
View article: PDL1 shapes the classical Hodgkin lymphoma microenvironment without inducing T-cell exhaustion
PDL1 shapes the classical Hodgkin lymphoma microenvironment without inducing T-cell exhaustion Open
Classical Hodgkin lymphoma (CHL) is unusually sensitive to PD1 inhibition and PDL1 is highly expressed on CHL cells and in the tumor microenvironment. This could be interpreted as evidence of exhaustion, but paradoxically, PD1+ lymphocyte …